-

Fresenius Kabi Selected to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi has been selected to exhibit the Ivenix Infusion System at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange on October 17, 2022, in Dallas.

The annual Innovative Technology Exchange offers selected suppliers the opportunity to demonstrate their technologies to supply chain and clinical leaders from Vizient’s member hospitals and subject matter experts who serve on their supply councils. Each technology will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to health care delivery or business models.

The Ivenix Infusion System from Fresenius Kabi is a large volume infusion pump supported by a management system specifically designed to simplify each step of infusion delivery and help eliminate unnecessary work while informing patient care teams.

To meaningfully impact medication safety, we reimagined the infusion process from beginning to end,” said Susan Niemeier, vice president, clinical excellence and product strategy for infusion systems at Fresenius Kabi. “Every aspect of the Ivenix Infusion System is designed to improve outcomes, prevent infusion-related errors and elevate the clinician experience. We look forward to sharing the Ivenix Infusion System with the participants of the Vizient Innovative Technology Exchange in October and demonstrating how we can transform infusion delivery together.”

“Suppliers apply to attend the Exchange hoping their product will be awarded an Innovative Technology contract, which signals health care providers of their product’s unique qualities,” said Kelly Flaharty, senior director of contract services, Vizient. “The selection process for suppliers who exhibit at the Exchange is rigorous, and this technology has earned its coveted invitation to the event.”

The annual Innovative Technology Exchange is part of Vizient’s Innovative Technology Program that includes product reviews of supplier-submitted technologies by member-led councils and task forces. Since 2003, Vizient has reviewed more than 1,600 product submissions as part of its Innovative Technology Program.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Contacts

Matt Kuhn
(847) 220-3033
matt.kuhn@fresenius-kabi.com

Fresenius Kabi


Release Versions

Contacts

Matt Kuhn
(847) 220-3033
matt.kuhn@fresenius-kabi.com

Social Media Profiles
More News From Fresenius Kabi

Fresenius Kabi and AABB Announce 21st Annual Blood Collectors Week, September 6–12, 2026, Honoring Lifesaving Blood Collection Professionals

LAKE ZURICH, Ill. & BETHESDA, Md.--(BUSINESS WIRE)--Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) announced today the launch of the 21st annual Blood Collectors Week, taking place September 6–12, 2026. The annual recognition week celebrates the blood collection professionals whose expertise and dedication help ensure patients across the country have access to safe, high-quality blood and blood components. Blood Collectors Week honors the essential pro...

Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, a global healthcare company part of the Fresenius Group, specializing in lifesaving therapies and technologies, today announced the U.S. launch of the FDA‑approved generic Sugammadex Injection. Exclusivity for the branded medicine Bridion® (Merck) expired in July 2026. Fresenius Kabi offers operating room clinicians Sugammadex in a Simplist® ready-to-administer prefilled syringe. Simplist® single-dose, prefilled syringes require no assembly at...

Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. Risk Statement: The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More se...
Back to Newsroom